This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Sep 14;382(9896):917-8.

doi: 10.1016/S0140-6736(13)60902-2. Epub 2013 Jul 12.

SGLT2 inhibitors for diabetes: turning symptoms into therapy

Michaela Diamant¹, Linde M Morsink

Affiliations

PMID: 23850056
DOI: 10.1016/S0140-6736(13)60902-2

Comment

SGLT2 inhibitors for diabetes: turning symptoms into therapy

Michaela Diamant et al. Lancet. 2013.

. 2013 Sep 14;382(9896):917-8.

doi: 10.1016/S0140-6736(13)60902-2. Epub 2013 Jul 12.

Authors

Michaela Diamant¹, Linde M Morsink

Affiliation

¹ Diabetes Centre, VU University Medical Centre, Amsterdam, 1018 HZ, Netherlands. m.diamant@vumc.nl

PMID: 23850056
DOI: 10.1016/S0140-6736(13)60902-2

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Cefalu WT, et al. Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12. Lancet. 2013. PMID: 23850055 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information